JHL1101

BIOLOGICAL3 trials

Sponsors

JHL Biotech, Inc.

Conditions

Arthritis, RheumatoidB Cell LymphomaDiffuse Large B-Cell LymphomaRheumatoid Arthritis

Phase 1

A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis

TerminatedNCT03161457

JHL Biotech, Inc.Arthritis, Rheumatoid, Rheumatoid Arthritis

Start: 2017-02-27End: 2019-04-16Updated: 2020-01-09

A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

TerminatedNCT03670888

JHL Biotech, Inc.B Cell Lymphoma

Start: 2018-11-16End: 2019-03-19Updated: 2020-01-09

Phase 3

A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

TerminatedNCT03670901

JHL Biotech, Inc.Diffuse Large B-Cell Lymphoma

Start: 2018-11-13End: 2019-03-07Updated: 2020-01-09